DOCSLIB.ORG

IDH1 and IDH2 Mutations in Myelodysplastic Syndromes and Role in Disease Progression

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IDH1 and IDH2 Mutations in Myelodysplastic Syndromes and Role in Disease Progression Letters to the Editor 980 3 Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D et al. 11 Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K et al. Widespread genetic heterogeneity in multiple myeloma: implications for targeted International uniform response criteria for multiple myeloma. Leukemia 2006; 20: therapy. Cancer Cell 2014; 25:91–101. 1467–1473. 4 Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al. 12 Annunziata CM, Hernandez L, Davis RE, Zingone A, Lamy L, Lam LT et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade Nat Commun 2014; 5: 2997. of MAF oncogene expression. Blood 2011; 117: 2396–2404. 5 Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al. Intraclonal 13 Barlogie B, Shaughnessy JD. Early results of total therapy II in multiple heterogeneity is a critical early event in the development of myeloma and myeloma: implications of cytogenetics and FISH. Int J Hematol 2002; 76 (Suppl 1): precedes the development of clinical symptoms. Leukemia 2014; 28: 384–390. 337–339. 6 Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J et al. Targeting 14 Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M et al. the BRAF V600E mutation in multiple myeloma. Cancer Discov 2013; 3:862–869. Incorporating bortezomib into upfront treatment for multiple myeloma: early 7 Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF results of total therapy 3. Br J Haematol 2007; 138:176–185. activate C-RAF through distinct mechanisms involving heterodimerization. Mol 15 Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D et al. Total Cell 2005; 20:963–969. therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 8 Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R et al. RAF 1999; 93:55–65. inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010; 464: 431–435. 9 Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, Kulkarni SG et al. This work is licensed under a Creative Commons Attribution- GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with NonCommercial-NoDerivs 4.0 International License. The images or favorable pharmacokinetic properties for sustained in vivo pathway inhibition. other third party material in this article are included in the article’s Creative Commons Clin Cancer Res 2011; 17: 989–1000. license, unless indicated otherwise in the credit line; if the material is not included under 10 Shaughnessy JD, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I et al. Avalidated the Creative Commons license, users will need to obtain permission from the license gene expression model of high-risk multiple myeloma is defined by deregulated holder to reproduce the material. To view a copy of this license, visit http:// expression of genes mapping to chromosome 1. Blood 2007; 109:2276–2284. creativecommons.org/licenses/by-nc-nd/4.0/ Supplementary Information accompanies this paper on the Leukemia website (http://www.nature.com/leu) IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression Leukemia (2016) 30, 980–984; doi:10.1038/leu.2015.211 sequencing confirmation (analytical sensitivity: 10–20%) as has been previously described.11 Beginning in September 2012, IDH1/2 testing was performed within a Clinical Laboratory Recurrent pathogenic mutations in IDH1 and IDH2 at the Improvements Ammendments-certified next-generation sequen- conserved amino acid sites IDH1-R132, IDH2-R140 and IDH2-R172 cing platform (analytical sensitivity: 2.5–5%). Statistical analyses 1 occur in ~ 20% of patients with acute myeloid leukemia (AML). were conducted in Statistica v12.0 (StatSoft Inc, Tulsa, OK, USA) A recent analysis of AML patients at our institution identified and significance defined as Po0.05. Overall survival (OS) was IDH1/2 mutations in 20% (n = 167) of 826 AML patients, with measured as the time from presentation to date of death or last IDH1/2 mutations occurring most frequently in the setting of follow-up, and progression-free survival from presentation to date diploid karyotype or other intermediate-risk cytogenetics, parti- of death, last follow-up, or date of progression to AML. Informed cularly trisomy 8 (77 vs 53%, Po0.0005). AML patients with IDH1/2 consent was obtained following institutional guidelines and in mutations were overall less likely to have a diagnosis of therapy- accordance with the Declaration of Helsinki. related AML (8 vs 17%, P = 0.003).2 Of the 1042 MDS patients, 60 patients (5.7%) had IDH1/2 Compared with their frequency in AML, IDH1/2 mutations are mutations identified. Specifically, 17 patients (1.6%) were IDH1- less common in myelodysplastic syndromes (MDS), occurring in R132 mutated and 43 patients (4.1%) had IDH2-R140 (n = 42) or ~ 5% of MDS patients, although an incidence as high as 12% has IDH2-R172 (n = 1) mutations, respectively. The clinicopathological – been reported.3 8 Although IDH1/2 mutations are thought to characteristics of patients with and without IDH1/2 mutations are represent early ‘driver’ events in leukemogenesis with mutational shown in Table 1. Within this cohort, 701 patients (67%) were stability over time, reports of IDH1/2 acquisition at the time of untreated and 341 (33%) had received systemic MDS therapy leukemic transformation in patients with myeloproliferative before presentation. MDS patients with IDH1/2 mutations had a neoplasms and MDS have been described.3,9,10 lower absolute neutrophil count (1.15 × 109/l vs 1.71 × 109/l, The purpose of this analysis is to evaluate the overall prevalence P = 0.02), higher bone marrow blast percentage (6 vs 4%, of IDH1/2 mutations in MDS patients treated at our institution, as P = 0.001), and a trend for higher platelet counts (99 × 109/l vs well as determine the incidence and frequency of IDH1/2 75 × 109/l, P = 0.07). mutations identified at the time of leukemic transformation in Of the 60 IDH1/2 mutations, 17 (28%) were present in the very MDS patients. low or low-risk IPSS-R groups, 15 (25%) intermediate, and 27 (45%) Eligible patients comprised all adults with histologically in the high or very-high IPSS-R prognostic score categories confirmed MDS treated at MD Anderson Cancer Center from (Table 1). While the distribution of IPSS-R categories among January 2010 to January 2015. A total of 1042 MDS patients with IDH1/2-mutants versus wild-type patients was similar, we identi- known IDH1 and IDH2 status were included. From January 2010 to fied a conspicuously different underlying pattern of cytogenetics September 2012, IDH1/2 molecular analysis was performed by and bone marrow blasts. Consistent with karyotypic patterns in high-resolution melting curve analysis followed by Sanger IDH1/2-mutant AML,2 the majority of IDH1/2-mutant MDS patients Accepted article preview online 31 July 2015; advance online publication, 21 August 2015 Leukemia (2016) 947 – 1002 © 2016 Macmillan Publishers Limited Letters to the Editor 981 Table 1. Clinicopathological characteristics of MDS study cohort (n = 1042) Characteristic IDH wild-type (n = 982) IDH-mutated (n = 60) P-valuea IDH1-mutated (n = 17) IDH2-mutated (n = 43) P-valuea Median age (range) 70 (17–90) 68 (32–85) 0.36 68 (57–78) 68 (32–85) 0.84 Male sex (%) 642 (65) 44 (73) 0.21 14 (82) 30 (70) 0.32 WBC count (×109/l) 3.6 (0.4–223.1) 2.5 (0.7–67.5) 0.12 2.1 (1.2–67.5) 3.2 (0.7–58.6) 0.08 ANC (×109/l) 1.71 (0.008–118.3) 1.15 (0.064–60.07) 0.02 0.97 (0.098–60.075) 1.23 (0.064–33.9) 0.31 PLT count (×109/l) 76 (3–1552) 99 (11–441) 0.07 99 (30–194) 101 (11–441) 0.98 BM blasts (%) 4 (0–38) 6 (1–18) 0.001 5(1–18) 7 (1–18) 0.41 PB blasts (%) 0 (0–29) 0 (0–14) 0.12 0 (0–3) 1 (0–14) 0.006 LDHb 536 (24–9329) 550 (278–2321) 0.37 534 (322–963) 580 (278–2321) 0.37 Cytogenetics; n (%) 0.023 0.97 Diploid or –Y 420 (43) 36 (60) 10 (59) 26 (60) Isolated del(5q) 23 (2) 0 (0) 0 (0) 0 (0) Double del(5q) 14 (1) 0 (0) 0 (0) 0 (0) Complex del(5q) 56 (6) 0 (0) 0 (0) 0 (0) Trisomy 8 73 (7) 6 (10) 2 (12) 4 (9) -7/7q or complex 135 (14) 3 (5) 1 (6) 2 (5) Isolated del(20q) 29 (3) 0 (0) 0 (0) 0 (0) Other intermediate 174 (18) 14 (23) 4 (24) 10 (23) -Not done,Inad. 58 (6) 1 (2) 0 (0) 1 (2) WHO category; n (%) 0.330 0.073 5q- 19 (2) 0 (0) 0 (0) 0 (0) CML Ph- 8 (1) 0 (0) 0 (0) 0 (0) CMML-1 100 (10) 6 (10) 0 (0) 6 (14) CMML-2 36 (4) 4 (7) 0 (0) 4 (9) MDS/MPD 23 (2) 1 (2) 1 (6) 0 (0) MDS-U 39 (4) 1 (2) 1 (6) 0 (0) RA 88 (9) 0 (0) 0 (0) 0 (0) RAEB-1 215 (22) 19 (32) 5 (29) 14 (33) RAEB-2 199 (20) 14 (23) 4 (24) 10 (23) RARS 35 (4) 3 (5) 0 (0) 3 (7) RCMD 196 (20) 11 (18) 5 (29) 6 (14) RCMD-RS 24 (2) 1 (2) 1 (6) 0 (0) IPSS-R 0.792 0.334 Very high 188 (19) 13 (22) 4 (24) 9 (21) High 195 (20) 14 (23) 1 (6) 13 (30) Intermediate 195 (20) 15 (25) 6 (35) 9 (21) Low 247 (25) 12 (20) 4 (24) 8 (19) Very low 91 (9) 5 (8) 2 (12) 3 (7) N/A 66 (7) 1 (2) 0 (0) 1 (2) Molecular KRAS/NRAS 73 (8) 7 (12) 0.25 1 (6) 6 (14) 0.37 JAK2 25 (3) 2 (3) 0.76 1 (6) 1 (2) 0.50 FLT3-ITD or D835 21 (2) 0 (0) 0.006 0 (0) 0 (0) n/a NPM1 9 (1) 1 (2) 0.54 0 (0) 1 (3) 0.54 TP53 73 (17) 0 (0) 0.006 0 (0) 0 (0) n/a RUNX1 24 (40) 3 (13) 0.015 1 (25) 2 (10) 0.41 ASXL1 37 (44) 5 (21) 0.039 2 (50) 3 (15) 0.12 TET2 53 (35) 2 (8) 0.008 0 (0) 2 (10) 0.51 DNMT3a 26 (6) 3 (7) 0.89 1 (7) 2 (6) 0.93 CEBPA 52 (6) 4 (8) 0.64 1 (7) 3 (8) 0.93 EZH2 13 (1) 0 (0) 0.36 0 (0) 0 (0) n/a Abbreviations: ANC, absolute neutrophil count; BM, bone marrow; LDH, lactate dehydrogenase; MDS, myelodysplastic syndromes; MPD, myeloproliferative disease; PB, peripheral blood; PLT, platelet; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, refractory cytopenia with multilineage dysplasia ring sideroblasts; WBC, white blood cell; WHO, World Health Organization.
Load more

Recommended publications
  • Download (Pdf)
    Invivoscribe's wholly-owned Laboratories for Personalized Molecular LabPMM LLC Medicine® (LabPMM) is a network of international reference laboratories that provide the medical and pharmaceutical communities with worldwide Located in San Diego, California, USA, it holds access to harmonized and standardized clinical testing services. We view the following accreditations and certifications: internationally reproducible and concordant testing as a requirement for ISO 15189, CAP, and CLIA, and is licensed to provide diagnostic consistent stratification of patients for enrollment in clinical trials, and the laboratory services in the states of California, Florida, foundation for establishing optimized treatment schedules linked to patient’s Maryland, New York, Pennsylvania, and Rhode Island. individual profile. LabPMM provides reliable patient stratification at diagnosis LabPMM GmbH and monitoring, throughout the entire course of treatment in support of Personalized Molecular Medicine® and Personalized Based in Martinsried (Munich), Germany. It is an ISO 15189 Molecular Diagnostics®. accredited international reference laboratory. CLIA/CAP accreditation is planned. Invivoscribe currently operates four clinical laboratories to serve partners in the USA (San Diego, CA), Europe (Munich, Germany), and Asia (Tokyo, Japan and Shanghai, China). These laboratories use the same critical LabPMM 合同会社 reagents and software which are developed consistently with ISO Located in Kawasaki (Tokyo), Japan and a licensed clinical lab. 13485 design control. Our cGMP reagents, rigorous standards for assay development & validation, and testing performed consistently under ISO 15189 requirements help ensure LabPMM generates standardized and concordant test results worldwide. Invivoscribe Diagnostic Technologies (Shanghai) Co., Ltd. LabPMM is an international network of PersonalMed Laboratories® focused on molecular oncology biomarker studies. Located in Shangai, China.
    [Show full text]
  • IDH2 Mutations—Co-Opting Cellular Metabolism for Malignant Transformation Eytan M
    Published OnlineFirst November 9, 2015; DOI: 10.1158/1078-0432.CCR-15-0362 Molecular Pathways Clinical Cancer Research Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation Eytan M. Stein Abstract Mutations in mitochondrial IDH2, one of the three isoforms function that catalyzes the conversion of alpha-ketoglutarate to of IDH, were discovered in patients with gliomas in 2009 and beta-hydroxyglutarate (2-HG). Supranormal levels of 2-HG subsequently described in acute myelogenous leukemia (AML), lead to hypermethylation of epigenetic targets and a subse- angioimmunoblastic T-cell lymphoma, chondrosarcoma, and quent block in cellular differentiation. AG-221, a small-mole- intrahepatic chloangiocarcinoma. The effects of mutations in cule inhibitor of mutant IDH2, is being explored in a phase I IDH2 on cellular metabolism, the epigenetic state of mutated clinical trial for the treatment of AML, other myeloid malig- cells, and cellular differentiation have been elucidated in vitro nancies, solid tumors, and gliomas. Clin Cancer Res; 22(1); 16–19. and in vivo.MutationsinIDH2 lead to an enzymatic gain of Ó2015 AACR. Background Interestingly, in a screen of 398 patients with AML, TET2 and IDH2 mutations were mutually exclusive, suggesting that these Isocitrate dehydrogenase (IDH) catalyzes the conversion of two mutations have a similar function. Wild-type TET2 demethy- isocitrate to alpha-ketoglutarate. IDH occurs in three isoforms, lates DNA, and mutations in TET2 lead to increases in 5-methyl- IDH1, located in the cytoplasm, IDH2 located in the mitochon- cytosine similar to those seen in patients with IDH mutations. It dria, and IDH3, which functions as part of the tricarboxylic acid has been suggested that elevated levels of 2-HG caused by mutant cycle.
    [Show full text]
  • Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia
    Src-Family Kinases Impact Prognosis and Targeted Therapy in Flt3-ITD+ Acute Myeloid Leukemia Title Page by Ravi K. Patel Bachelor of Science, University of Minnesota, 2013 Submitted to the Graduate Faculty of School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Pittsburgh 2019 Commi ttee Membership Pa UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE Commi ttee Membership Page This dissertation was presented by Ravi K. Patel It was defended on May 31, 2019 and approved by Qiming (Jane) Wang, Associate Professor Pharmacology and Chemical Biology Vaughn S. Cooper, Professor of Microbiology and Molecular Genetics Adrian Lee, Professor of Pharmacology and Chemical Biology Laura Stabile, Research Associate Professor of Pharmacology and Chemical Biology Thomas E. Smithgall, Dissertation Director, Professor and Chair of Microbiology and Molecular Genetics ii Copyright © by Ravi K. Patel 2019 iii Abstract Src-Family Kinases Play an Important Role in Flt3-ITD Acute Myeloid Leukemia Prognosis and Drug Efficacy Ravi K. Patel, PhD University of Pittsburgh, 2019 Abstract Acute myelogenous leukemia (AML) is a disease characterized by undifferentiated bone-marrow progenitor cells dominating the bone marrow. Currently the five-year survival rate for AML patients is 27.4 percent. Meanwhile the standard of care for most AML patients has not changed for nearly 50 years. We now know that AML is a genetically heterogeneous disease and therefore it is unlikely that all AML patients will respond to therapy the same way. Upregulation of protein-tyrosine kinase signaling pathways is one common feature of some AML tumors, offering opportunities for targeted therapy.
    [Show full text]
  • Reprogramming of Isocitrate Dehydrogenases Expression and Activity by the Androgen
    Author Manuscript Published OnlineFirst on May 8, 2019; DOI: 10.1158/1541-7786.MCR-19-0020 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 1 Reprogramming of isocitrate dehydrogenases expression and activity by the androgen 2 receptor in prostate cancer 3 4 Kevin Gonthier1,2, Raghavendra Tejo Karthik Poluri1,2, Cindy Weidmann1, Maude Tadros1, and 5 Étienne Audet-Walsh1,2,3 6 7 1 Endocrinology - Nephrology Research Axis, Centre de recherche du CHU de Québec - 8 Université Laval, Québec City, Canada 9 2 Department of molecular medicine, Faculty of Medicine, Université Laval, Québec City, 10 Canada 11 3 Centre de recherche sur le cancer de l’Université Laval, Québec City, Canada 12 13 Keywords: steroid; metabolism; glioma; nuclear receptor; castration-resistant prostate cancer, 14 IDH1, oncometabolism 15 16 Abbreviated title: Reprogramming of IDH activity by AR in PCa 17 18 Corresponding Author: Étienne Audet-Walsh, Centre de recherche du CHU de Québec, 2705 19 Boulevard Laurier, room R-4714, Québec City, QC, Canada, G1V 4G2 20 Phone: 1-418-525-4444 ext. 48678 ; e-mail : [email protected] 21 22 Disclosure statement: the authors declare no potential conflicts of interest. 1 Downloaded from mcr.aacrjournals.org on September 24, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 8, 2019; DOI: 10.1158/1541-7786.MCR-19-0020 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 23 Abstract 24 Mutations of the isocitrate dehydrogenase genes IDH1 and IDH2, key enzymes involved in 25 citrate metabolism, are important oncogenic events in several cancer types, including in 1-3% of 26 all prostate cancer (PCa) cases.
    [Show full text]
  • Potential Genotoxicity from Integration Sites in CLAD Dogs Treated Successfully with Gammaretroviral Vector-Mediated Gene Therapy
    Gene Therapy (2008) 15, 1067–1071 & 2008 Nature Publishing Group All rights reserved 0969-7128/08 $30.00 www.nature.com/gt SHORT COMMUNICATION Potential genotoxicity from integration sites in CLAD dogs treated successfully with gammaretroviral vector-mediated gene therapy M Hai1,3, RL Adler1,3, TR Bauer Jr1,3, LM Tuschong1, Y-C Gu1,XWu2 and DD Hickstein1 1Experimental Transplantation and Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA and 2Laboratory of Molecular Technology, Scientific Applications International Corporation-Frederick, National Cancer Institute-Frederick, Frederick, Maryland, USA Integration site analysis was performed on six dogs with in hematopoietic stem cells. Integrations clustered around canine leukocyte adhesion deficiency (CLAD) that survived common insertion sites more frequently than random. greater than 1 year after infusion of autologous CD34+ bone Despite potential genotoxicity from RIS, to date there has marrow cells transduced with a gammaretroviral vector been no progression to oligoclonal hematopoiesis and no expressing canine CD18. A total of 387 retroviral insertion evidence that vector integration sites influenced cell survival sites (RIS) were identified in the peripheral blood leukocytes or proliferation. Continued follow-up in disease-specific from the six dogs at 1 year postinfusion. A total of 129 RIS animal models such as CLAD will be required to provide an were identified in CD3+ T-lymphocytes and 102 RIS in accurate estimate
    [Show full text]
  • As a Potential Therapeutic Approach for AML Wittawat Chantkran 1,2,Ya-Chinghsieh1, Daniella Zheleva3,Sheelaghframe3, Helen Wheadon1 and Mhairi Copland 1
    Chantkran et al. Cell Death Discovery (2021) 7:137 https://doi.org/10.1038/s41420-021-00496-y Cell Death Discovery ARTICLE Open Access Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML Wittawat Chantkran 1,2,Ya-ChingHsieh1, Daniella Zheleva3,SheelaghFrame3, Helen Wheadon1 and Mhairi Copland 1 Abstract Over the last 50 years, there has been a steady improvement in the treatment outcome of acute myeloid leukemia (AML). However, median survival in the elderly is still poor due to intolerance to intensive chemotherapy and higher numbers of patients with adverse cytogenetics. Fadraciclib (CYC065), a novel cyclin-dependent kinase (CDK) 2/9 inhibitor, has preclinical efficacy in AML. In AML cell lines, myeloid cell leukemia 1 (MCL-1) was downregulated following treatment with fadraciclib, resulting in a rapid induction of apoptosis. In addition, RNA polymerase II (RNAPII)-driven transcription was suppressed, rendering a global gene suppression. Rapid induction of apoptosis was observed in primary AML cells after treatment with fadraciclib for 6–8 h. Twenty-four hours continuous treatment further increased efficacy of fadraciclib. Although preliminary results showed that AML cell lines harboring KMT2A rearrangement (KMT2A-r) are more sensitive to fadraciclib, we found that the drug can induce apoptosis and decrease MCL-1 expression in primary AML cells, regardless of KMT2A status. Importantly, the diversity of genetic mutations observed in primary AML patient samples was associated with variable response to fadraciclib, confirming the need for fi 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; patient strati cation to enable a more effective and personalized treatment approach. Synergistic activity was demonstrated when fadraciclib was combined with the BCL-2 inhibitor venetoclax, or the conventional chemotherapy agents, cytarabine, or azacitidine, with the combination of fadraciclib and azacitidine having the most favorable therapeutic window.
    [Show full text]
  • Mouse Idh3a Mutations Cause Retinal Degeneration and Reduced Mitochondrial Function Amy S
    © 2018. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2018) 11, dmm036426. doi:10.1242/dmm.036426 RESEARCH ARTICLE Mouse Idh3a mutations cause retinal degeneration and reduced mitochondrial function Amy S. Findlay1, Roderick N. Carter2, Becky Starbuck3, Lisa McKie1, Klára Nováková1, Peter S. Budd1, Margaret A. Keighren1, Joseph A. Marsh1, Sally H. Cross1, Michelle M. Simon3, Paul K. Potter3, Nicholas M. Morton2 and Ian J. Jackson1,4,* ABSTRACT these diseases have a wide range of pathologies (Koopman et al., Isocitrate dehydrogenase (IDH) is an enzyme required for the 2012). Common to many of the diseases, however, are neurological production of α-ketoglutarate from isocitrate. IDH3 generates the or neuromuscular manifestations, including retinal disease. We have NADH used in the mitochondria for ATP production, and is a tetramer identified a missense mutation in the gene encoding a subunit of the made up of two α, one β and one γ subunit. Loss-of-function and tricarboxylic acid (TCA) cycle enzyme isocitrate dehydrogenase 3 missense mutations in both IDH3A and IDH3B have previously been (IDH3) as causing a retinal degeneration phenotype in mice. There implicated in families exhibiting retinal degeneration. Using mouse are three isocitrate dehydrogenase isozymes in mammals. IDH1 and models, we investigated the role of IDH3 in retinal disease and IDH2 are both homodimers that catalyse the decarboxylation of α mitochondrial function. We identified mice with late-onset retinal isocitrate to -ketoglutarate with the concomitant reduction of NADP degeneration in a screen of ageing mice carrying an ENU-induced to NADPH. IDH1 is cytoplasmic, whereas IDH2 is localised to the mutation, E229K, in Idh3a.
    [Show full text]
  • S6K1 Mediates Oncogenic Glycolysis in Pten Deficient Leukemia
    S6K1 mediates oncogenic glycolysis in Pten deficient leukemia A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Ph.D.) in the Department of Cancer and Cell Biology of the College of Medicine by Preeti Tandon M.S. Bowling Green State University, 2004 ABSTRACT Hyperactive Akt signaling triggers glycolysis and apoptosis resistance in human cancer. Because sustained glycolysis is required for Akt dependent apoptosis resistance, we investigated the downstream signaling components that mediate Akt dependent increases in glycolysis in cells deficient for Pten, a negative regulator of the PI3K/Akt pathway. Genetic inactivation of the ribosomal protein S6 Kinase 1 (S6K1) in Pten-deficient cells prevented glycolysis, triggered Bax translocation and committed cells to apoptosis. Pharmacological S6K1 inhibition using a small molecule kinase inhibitor recapitulated the effects of genetically inactivating S6K1. Inactivation of S6K1 was associated with decreased expression of the pro-glycolytic HIF1α transcription factor. Restoring HIF1α expression was sufficient to restore both glycolysis and cell survival in S6K1-deficient cells. Conversely, inhibiting HIF1α expression in Pten deficient cells resulted in decreased glycolysis and cell survival, mimicking the loss of S6K1. In vivo, S6K1 deficiency delayed the development of lethal disease in a Pten deficient mouse model of leukemia. Thus, together the data suggest that S6K1 is a useful target for counteracting the metabolic program that supports apoptosis resistance in Pten-deficient cancers. iii iv ACKNOWLEDGEMENTS I would first and foremost like to thank Dr David Plas for being my mentor. Your guidance and advice have been instrumental in my progress and development as a scientist.
    [Show full text]
  • Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Acute
    Integrative Cancer Science and Therapeutics Review Article ISSN: 2056-4546 Targeting the phosphatidylinositol 3-kinase signaling pathway in acute myeloid leukemia Ota Fuchs* Institute of Hematology and Blood Transfusion, Prague, Czech Republic Abstract The phosphatidylinositol-3-kinase-Akt (protein kinase B) - mechanistic target of rapamycin (PI3K-Akt-mTOR) pathway is often dysregulated in cancer, including hematological malignancies. Primary acute myeloid leukemia (AML) cell populations may include various subclones at the time of diagnosis. A relapse can occur due to regrowth of the originally dominating clone, a subclone detectable at the time of first diagnosis, or a new clone derived either from the original clone or from remaining preleukemic stem cells. Inhibition of mTOR signaling has in general modest growth-inhibitory effects in preclinical AML models and clinical trials. Therefore, combination of allosteric mTOR inhibitors with standard chemotherapy or targeted agents has a greater anti-leukemia efficacy. Dual mTORC1/2 inhibitors, and dual PI3K/mTOR inhibitors show greater activity in pre-clinical AML models. Understanding the role of mTOR signaling in leukemia stem cells is important because AML stem cells may become chemoresistant by displaying aberrant signaling molecules, modifying epigenetic mechanisms, and altering the components of the bone marrow microenvironment. The PI3K/Akt/mTOR signaling pathway is promising target in the treatment of hematological malignancies, including AML, especially by using of combinations of mTOR inhibitors with conventional cytotoxic agents. Introduction syndromes, chronic myelogenous leukemia (CML), multiple myeloma and lymphoid leukemias and lymphomas [42-54]. Below, I discuss the The mammalian target of rapamycin (mTOR) is a serine/threonine PI3K/Akt/mTOR pathway and its role in AML.
    [Show full text]
  • Abbott Realtime IDH2 Labeling
    1.0 Abbott RealTime IDH2 Labeling 1.1 Abbott RealTime IDH2 Amplification Reagent Kit Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 2 of 35 1.2 Abbott RealTime IDH2 Oligonucleotide Reagent 1 Label 1.3 Abbott RealTime IDH2 Oligonucleotide Reagent 2 Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 3 of 35 1.4 Abbott RealTime IDH2 Oligonucleotide Reagent 3 Label 1.5 Abbott RealTime IDH2 Oligonucleotide Reagent 4 Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 4 of 35 1.6 Abbott RealTime IDH2 Activation Reagent Label 1.7 Abbott RealTime IDH2 DNA Polymerase Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 5 of 35 1.8 Abbott RealTime IDH2 Control Kit Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 6 of 35 1.9 Abbott RealTime IDH2 Positive Control Label 1.10 Abbott RealTime IDH2 Negative Control Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 7 of 35 1.11 Abbott RealTime IDH2 m2000rt Application CD-ROM Disc Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 8 of 35 1.12 Abbott RealTime IDH2 m2000rt Application CD-ROM Carton Label Abbott RealTime IDH2 PMA 170005 - Amendment 2 August 2017 Volume 1 001_Administrative Documents and IDH2 PMA Amendment 2_mw001 Page 9 of 35 Abbott RealTime IDH2 m 2000rt Application CD-ROM 08N82-001 Version 1.0 51-603271/R1 08N82-001 51-603271/R1 Intended Use Key to Symbols Used The Abbott RealTime IDH2 m2000rt Application CD-ROM, Version 1.0 (List No.
    [Show full text]
  • In Silico Analysis of IDH3A Gene Revealed Novel Mutations Associated with Retinitis Pigmentosa
    bioRxiv preprint doi: https://doi.org/10.1101/554196; this version posted February 18, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. In silico analysis of IDH3A gene revealed Novel mutations associated with Retinitis Pigmentosa Thwayba A. Mahmoud1*, Abdelrahman H. Abdelmoneim1, Naseem S. Murshed1, Zainab O. Mohammed2, Dina T. Ahmed1, Fatima A. Altyeb1, Nuha A. Mahmoud3, Mayada A. Mohammed1, Fatima A. Arayah1, Wafaa I. Mohammed1, Omnia S. Abayazed1, Amna S. Akasha1, Mujahed I. Mustafa1,4, Mohamed A. Hassan1 1- Department of Biotechnology, Africa city of Technology, Sudan 2- Hematology Department, Ribat University Hospital, Sudan 3- Biochemistry Department, faculty of Medicine, National University, Sudan 4- Department of Biochemistry, University of Bahri, Sudan *Corresponding Author: Thwayba A. Mahmoud, Email: [email protected] Abstract: Background: Retinitis Pigmentosa (RP) refers to a group of inherited disorders characterized by the death of photoreceptor cells leading to blindness. The aim of this study is to identify the pathogenic SNPs in the IDH3A gene and their effect on the structure and function of the protein. Method: we used different bioinformatics tools to predict the effect of each SNP on the structure and function of the protein. Result: 20 deleterious SNPs out of 178 were found to have a damaging effect on the protein structure and function. Conclusion: this is the first in silico analysis of IDH3A gene and 20 novel mutations were found using different bioinformatics tools, and they could be used as diagnostic markers for Retinitis Pigmentosa.
    [Show full text]
  • Wild-Type and Mutated IDH1/2 Enzymes and Therapy Responses
    Oncogene (2018) 37:1949–1960 https://doi.org/10.1038/s41388-017-0077-z REVIEW ARTICLE Corrected: Correction Wild-type and mutated IDH1/2 enzymes and therapy responses 1,2,3 3 2 1 Remco J. Molenaar ● Jaroslaw P. Maciejewski ● Johanna W. Wilmink ● Cornelis J.F. van Noorden Received: 22 September 2017 / Revised: 2 November 2017 / Accepted: 7 November 2017 / Published online: 25 January 2018 © The Author(s) 2018. This article is published with open access Abstract Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of D-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed. 1234567890();,: Introduction production of D-2HG is essentially a gain of function that is exclusive to mutant IDH1/2 enzymes, it was quickly rea- Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes lized that these frequently-occurring genetic alterations that function at a crossroads of cellular metabolism, epi- were promising targets for personalized anti-cancer therapy genetic regulation, redox states, and DNA repair. Mutations with small-molecule inhibitors [13].
    [Show full text]